B+
Bull case
30%
Probability
Target price
$44.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
VCEL
VericelCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The cleanest bullish read-through is that Vericel converted strong Q1 demand into a revenue guidance raise, maintained profitability targets, showed 72% gross margin, and exited the quarter with about $211M in cash and investments and no debt [#8-K-2026-05-07]. Record MACI biopsies, implants, and surgeon metrics support the commercial expansion thesis.
Posture
Mixed
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +9.7.
What can break
BARDA-related upside is not fully de-risked because optional funding, development milestones, and a potential U.S.-based manufacturing buildout depend on program execution [#PR-2026-04-02].
Momentum
16
Value
60
Sentiment
58
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $37.00 · Bull $44.00 · Bear $29.00Analysis 2026-05-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $60.57
Why
Momentum16 · Δ7d +0.5
Value60 · Δ7d -0.0
Sentiment58 · Δ7d +9.7
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +9.7.
Contradictions & invalidation
- • BARDA-related upside is not fully de-risked because optional funding, development milestones, and a potential U.S.-based manufacturing buildout depend on program execution [#PR-2026-04-02].
- • MACI Arthro, Epicel, and NexoBrid adoption must continue to offset a higher operating-cost base from sales-force expansion and the new Burlington facility [#8-K-2026-05-07].
- • The stock still faces execution risk because Q1 remained GAAP loss-making, operating expenses rose on sales-force expansion and Burlington facility costs, and forward growth still depends on surgeon adoption, manufacturing scale-up, and NexoBrid supply and reimbursement execution [#8-K-2026-05-07].
Catalyst clock
2026-05-08
Q1 beat-and-raise needs price confirmation
Lead driver: Sentiment · See AI snapshot
Momentum
16
9% active weight
Current posture
7d trendImproving
Δ7d
+0.5
Δ21d
-38.8
Value
60
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.8
Sentiment
58
62% active weight
Current posture
7d trendImproving
Δ7d
+9.7
Δ21d
+16.3
Why this grade
Composite grade C. Momentum 15.8 / Value 59.9 / Sentiment 57.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-05-08. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$37.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$29.00
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$2.23B
Beta
1.25
Shares Out
51.21M
P/E (TTM)
198.1
P/S (TTM)
7.25
P/FCF (TTM)
92.03
Rev YoY
+22.5%
EPS YoY
-483.6%
Gross Margin
+74.6%
Op Margin
+6.0%
Net Debt
-$39.23M
Current Ratio
5.04
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data